A Multi-dose Study on the Safety and Efficacy of Self-administered Intranasal AD17002 Treatment for Eosinophilic Asthma

NCT07250594 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

126

Enrollment

INDUSTRY

Sponsor class

Conditions

Eosinophilic Asthma

Interventions

BIOLOGICAL: AD17002
OTHER: Formulation buffer

Sponsor

Advagene Biopharma Co. Ltd.